

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

**CHANGE OF JOINT COMPANY SECRETARY,
PROCESS AGENT AND AUTHORISED REPRESENTATIVE**

**CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORISED
REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Directors**”) of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) announces that Ms. Ko Mei Ying (“**Ms. Ko**”) has resigned from the following positions of the Company to devote more time to pursue her personal commitments, with effect from August 22, 2024:

- (i) joint company secretary (the “**Joint Company Secretary**”);
- (ii) agent for the service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) as required under Rule 19A.13(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and
- (iii) authorised representative (the “**Authorised Representative**”) pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 3.05 of Listing Rules.

The Board further announces that, following the resignation of Ms. Ko, Mr. Li Kin Wai (“**Mr. Li**”) has been appointed as the Joint Company Secretary, the Process Agent and the Authorised Representative, with effect from August 22, 2024.

Ms. Ko has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and/or the shareholders of the Company.

After the aforesaid changes, Mr. Qin Xue (“**Mr. Qin**”) will continue to serve as the other Joint Company Secretary.

Profile of Mr. Qin

Mr. Qin has been a deputy general manager and the chief financial officer of the Group since he joined the Group on May 28, 2021. He is responsible for overseeing the financial and accounting affairs of the Group. He is also the Joint Company Secretary. Mr. Qin joined Lepu Medical Technology (Beijing) Co., Ltd.# (樂普(北京)醫療器械股份有限公司) (“**Lepu Medical**”) and its subsidiaries in April 2007 and served as a manager of the financial department in Lepu Medical until September 2012. Mr. Qin served as Lepu Medical’s manager of the financial planning department from October 2012 to June 2015, deputy director of financial management and manager of the fund management department from July 2015 to February 2018, and internal audit director from March 2018 to April 2021, respectively. Mr. Qin graduated from Capital University of Economics and Business in China (首都經濟貿易大學) with a bachelor’s degree in Accounting in July 1999. He obtained qualifications as a senior accountant in July 2010 and certified management accountant (CMA) in October 2019.

Profile of Mr. Li

Mr. Li is currently a senior manager of the Company Secretarial Services of Tricor Services Limited, an integrated provider offering business, corporate and investor services. Mr. Li has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Mr. Li is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the announcement of the Company dated July 18, 2023 in relation to, among other things, the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Mr. Qin to act as the Joint Company Secretary for a period from July 18, 2023 to November 7, 2025 (the “**Waiver Period**”), subject to the conditions that (i) Mr. Qin will be assisted by Ms. Ko during the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

In view of Ms. Ko’s resignation and since Mr. Qin does not possess the qualifications of company secretary as required under Rule 3.28 of the Listing Rules, the Company has applied for, and the Stock Exchange has granted, a new waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the “**New Waiver**”) for a period from the date of the said appointment of Mr. Li to November 7, 2025 (the “**Remaining Waiver Period**”) on the conditions that (i) Mr. Qin must be assisted by Mr. Li during the Remaining Waiver Period; and (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company. The Stock Exchange expects that before the end of the Remaining Waiver Period, the Company will be able to demonstrate and seek the Stock Exchange’s confirmation that Mr. Qin having had the benefit of Mr. Li’s assistance during the Remaining Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 such that a further waiver will not be necessary; and the Company will disclose details of the New Waiver, including the reasons for, and the details and the conditions of the New Waiver and the qualification and experience of both Mr. Qin and Mr. Li, by way of announcement. The Stock Exchange may withdraw or change the New Waiver if the Company’s situation changes and the New Waiver would be revoked immediately if and when Mr. Li ceases to be the Joint Company Secretary.

REASONS AND GROUNDS FOR SEEKING THE NEW WAIVER

Mr. Li, the newly appointed Joint Company Secretary, meets the requirements under Rule 3.28 of the Listing Rules. Mr. Li, as a Joint Company Secretary, will work closely with, and provide assistance to Mr. Qin in discharging his duties as a Joint Company Secretary.

Although Mr. Qin does not possess the specified qualifications that are usually considered to be acceptable under Rule 3.28 of the Listing Rules, the Company considers that Mr. Qin, by virtue of his professional knowledge and experience in handling its corporate governance matters and with the support to be rendered by Mr. Li and his working team at Tricor Services Limited, would be capable of discharging his functions as a Joint Company Secretary.

The Company will ensure that Mr. Qin continues to have access to the relevant training and support in relation to the Listing Rules and the duties required of a company secretary of an issuer listed on the Stock Exchange. Mr. Qin and Mr. Li will take no less than 15 hours of professional training on any latest developments on the applicable Hong Kong laws and regulations in each financial year, in order to strengthen their experience and knowledge in respect of their duties and responsibilities under the Listing Rules.

Both Mr. Qin and Mr. Li will be advised by the Company's Hong Kong legal advisers, as and when appropriate and required respectively.

The Board wishes to take this opportunity to express its gratitude to Ms. Ko for her contribution during her tenure of offices and express its warmest welcome to Mr. Li for taking up the appointment.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
August 22, 2024

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. ZHENG Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*

For identification purposes only